Market Overview

Thermo Fisher Scientific to Sell its Cell Culture, Gene Modulation and Magnetic Beads Businesses to GE Healthcare for $1.06B

Share:
Related TMO
Benzinga's Top Upgrades, Downgrades For May 19, 2017
Wall Street's M&A Chatter From May 15: Thermo Fisher-Patheon, La Quinta, China Automotive Systems

Thermo Fisher Scientific (NYSE: TMO) today announced that it has signed an agreement to sell its
cell culture (sera and media), gene modulation and magnetic beads
businesses to GE Healthcare, a unit of General Electric Company (NYSE: GE), for approximately $1.06 billion. The businesses will become part of
GE Healthcare's Life Sciences division.

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global

 

Related Articles (LIFE + GE)

View Comments and Join the Discussion!